Search

Today MSK issued a statement regarding its financial results for its fiscal year 2025.

… Tuesday, March 31, 2026 MSK reported a deficiency of operating revenues over expenses totaling ($47.9) million and an operating cash flow margin of 3.7% for 2025. These results reflect planned one-time investments related to the go-live of the Epic electronic health record (EHR) system alongside higher

Learn how an MSK lab discovery in 2013 paved the way for the approval of a new breast cancer drug 10 years later.

… Wednesday, May 3, 2023 Earlier this year, the U.S. Food and Drug Administration (FDA) approved the drug elacestrant (Orserdu™) for certain people with advanced or metastatic breast cancer (stages 3 and 4). Elacestrant was effective in patients whose tumors were ER-positive , HER2-negative ; had continued

Learn what sets care for pituitary tumors apart from the rest at Memorial Sloan Kettering’s Multidisciplinary Pituitary and Skull Base Tumor Center.

… Wednesday, September 4, 2019 Summary Tumors in the pituitary gland require skilled care from a coordinated team. Experts at MSK’s Multidisciplinary Pituitary and Skull Base Tumor Center explain why. VIDEO | 01:36 About Your Transsphenoidal Surgery Learn about transsphenoidal surgery at MSK in this short

In 2009, Memorial Sloan Kettering established the nurse-led Cancer and Fertility Program to overcome barriers to getting information and provide resources to help clinicians have discussions about fertility options with their patients.

… Thursday, August 24, 2017 Access to information about fertility preservation and family-building options before and after cancer treatment is a key factor in the psychological wellbeing of young patients. But, unfortunately many of them don’t get adequate advice at the time that they need it. Each year

An MSK study reveals new details about how pancreatic cells carrying oncogenic mutations transition from benign to malignant — shining new light on the ecosystems that supports emerging tumors.

… Wednesday, April 15, 2026 As we age, our cells accumulate genetic changes — mutations — some of which open the door to cancer. Scientists call these mutations “oncogenic,” meaning “tumor producing.” By our senior years, we each may harbor as many as 100 billion cells with at least one oncogenic mutation

In her role at MSK, Mack will direct the evolution and improvement of all business processes.

… Monday, March 27, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that LaKisha Mack, MSHA , has joined the institution as the inaugural Chief Administrative Officer (CAO). A seasoned healthcare business leader with more than two decades of experience in institutional finance, operations

New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published today in the New England Journal of Medicine.

… Wednesday, June 2, 2021 New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD , and colleagues found that patients who received nivolumab (Opdivo®)  after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research

The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program will facilitate tailored mentorship with MSK faculty, while providing access to MSK’s drug development expertise, resources, and a pathway for future collaboration in the MSK Therapeutics Accelerator.

… Friday, February 6, 2026 The MSK Therapeutics Accelerator is accepting applications to its 2026 Cohort Program from pharmaceutical and biotech companies eager to accelerate and de-risk the development of innovative therapeutics for people with cancer. Scheduled to begin in June, the 2026 Cohort Program

During the height of the COVID-19 pandemic, when the constant sound of sirens filled the streets of New York City, Memorial Sloan Kettering Deputy Chief Nurse Kevin Browne found himself in a somewhat unfamiliar place: in the back of an ambulance headed to MSK—this time as a patient. 

… Friday, October 9, 2020 During the height of the COVID-19 pandemic, when the constant sound of sirens filled the streets of New York City and the surrounding communities, Memorial Sloan Kettering Deputy Chief Nurse Kevin Browne found himself in a somewhat unfamiliar place: in the back of an ambulance

In April 2022, the FDA approved the immunotherapy drug axicabtagene ciloleucel (Yescarta®) for the treatment of diffuse large B cell lymphoma earlier in the course of disease. Retired teacher and basketball coach Joe Crimi is one of the patients who benefited from this treatment.

… Thursday, May 5, 2022 When Joe Crimi found out that his lymphoma had returned after he’d been in remission for almost a year, he was “pretty depressed,” he remembers. His doctor at the hospital on Long Island where he’d received his initial treatment told him he would probably need a bone marrow transplant